TITLE

Pfizer Responds

AUTHOR(S)
Kerins Jr., Raymond F.
PUB. DATE
January 2009
SOURCE
Forbes Asia;1/12/2009, Vol. 5 Issue 1, p6
SOURCE TYPE
Periodical
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article "Day of Reckoning" in the December 8, 2008 issue.
ACCESSION #
36271599

 

Related Articles

  • Orphan products: an emerging trend in drug approvals. Coté, Timothy; Kelkar, Aditya; Kui Xu; Braun, M. Miles; Phillips, M. Ian // Nature Reviews Drug Discovery;Jan2010, Vol. 9 Issue 1, p84 

    A letter to the editor is presented in response to the article about the emerging trend in drug approvals in the U.S. in the 2008 issue.

  • Let cost effectiveness models be open to scrutiny. Poole, Chris; Agrawal, Samir; Currie, Craig J. // BMJ: British Medical Journal (International Edition);10/13/2007, Vol. 335 Issue 7623, p735 

    A letter to the editor is presented commenting on the ruling of Britain's National Institute for Health and Clinical Excellence (NICE) regarding the non-approval of donezepil for the treatment of Alzheimer's disease.

  • Oncologists and top-ups. Warren, Virginia J. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/27/2009, Vol. 338 Issue 7710, p1517 

    A letter to the editor is presented about the position of oncologists in Great Britain on the use of off-label drugs for treating malignant disease.

  • Drugs Down Under. Wonder, Michael J.; Wyber, Debbie // Health Affairs;Jul/Aug2006, Vol. 25 Issue 4, p1185 

    A letter to the editor is presented in response to an article about the centralized drug review process of four Commonwealth countries, which appeared in the March/April 2006 issue of the periodical.

  • Drugs Down Under: The Authors Respond. Morgan, Steve // Health Affairs;Jul/Aug2006, Vol. 25 Issue 4, p1185 

    A response by the author to a letter to the editor about the article on the centralized drug review process of four Commonwealth countries, which appeared in the March/April 2006 issue of the periodical is presented.

  • Postapproval Drug Safety. Abraham, Ivo L.; MacDonald, Karen M. // Health Affairs;Jul/Aug2006, Vol. 25 Issue 4, p1186 

    A letter to the editor is presented in response to an article about spending for post-approval drug safety, which appeared in the March/April 2006 issue of the periodical.

  • Postapproval Drug Safety: The Authors Respond. Ridley, David B.; Kramer, Judith M. // Health Affairs;Jul/Aug2006, Vol. 25 Issue 4, p1187 

    A response by the authors to a letter to the editor about their article on spending for post-approval drug safety, which appeared in the March/April 2006 issue of the periodical is presented.

  • Out-of-hours GPs don't need records access. Carri, Mark // Pulse;2/15/2012, Vol. 72 Issue 6, p15 

    A letter to the editor is presented in response to the article "Summary Care Record improving GP out-of-hours prescribing" in the previous issue.

  • Pay for Performance. Smith, Lloyd S.; Gosnay, Richard; Udell, Elliot // Podiatry Management;Mar2008, Vol. 27 Issue 3, p26 

    A letter to the editor is presented about a report that several pharmaceutical companies in France and Great Britain had their drugs approved for use and payment by their respective national healthcare services provided they met certain performance standards in patients.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics